grail
-
Grail’s liquid biopsy test shows high sensitivity in early cancer detection
The company plans to present early data in a poster on Saturday showing no more than 1 percent of tests generated false-positive results across 12 solid tumor and blood cancers.
-
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
-
Biopharma 1H18 Series A investment exceeds funding for all of 2017
Investment could be called frothy, but hasn’t reached bubble territory yet, SVB report author says.
-
The 10 largest biotech and devices VC investments in Q2
The most recent MoneyTree report from PwC and CB Insights highlights the biggest biotech-related and medical devices VC deals in Q2, which include investments in companies like Grail, Allogene Therapeutics, RefleXion Medical and Mevion Medical Systems.
-
Billion-dollar cancer detection startup Grail names new CEO with commercial chops
After the surprise departure of its founding CEO in August, Illumina spin-out Grail has named Roche/Genentech’s Global Head of Clinical Operations Jennifer Cook as its new leader.
-
Startups, Devices & Diagnostics
In an era of mega-rounds, Roivant Sciences still makes a splash with $1.1B haul
Billion-dollar private venture capital rounds are apparently now a “thing.” Roivant sealed the deal on Wednesday, following a multi-year trend towards bigger investment rounds in the life sciences.
-
Grail’s high profile CEO steps down after 18-month tenure
Illumina spin-out Grail revealed Wednesday that Jeff Huber is stepping down as CEO of the billion-dollar early cancer detection startup.
-
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
-
Healthcare is looking to the tech world for recruitment purposes
Providence St. Joseph Health recently hired Microsoft executive Venkat Bhamidipati as CFO. His appointment points to a trend of healthcare organizations eyeing the tech sector for new talent.
-
With $360M in new financing, Guardant Health prepares to sequence one million cancer patients
Guardant Health has unveiled an ambitious five-year plan to sequence tumor DNA from one million cancer patients. Dubbed “Guardant 1 million,” the push will be financed with $360 million in new financing from a broad syndicate of investors.
-
Grail initiates massive multicenter breast cancer study
The results of the study will serve as a baseline measure for detecting breast cancer in the blood and inform the development of Grail’s pan-cancer screening test.
-
Report: Digital health startups raise $2.5B in Q1 even as deal volume declines to six-year low
For the first time, population health startups attracted more investment than other digital health subsectors,
-
Behind Grail, Illumina’s billion-dollar diagnostics startup
With a billion dollars in private financing and a test projected to generate a terabyte of data per person, Grail has seeded a new category of diagnostics and Big Data. Despite this, the company story shared by CEO Jeff Huber is mostly about people.
-
From Grail to Freenome, liquid biopsies seize the day
Wednesday was just short of a billion-dollar day for liquid biopsy companies, with a $65 million Series A announcement from Freenome and a $900 million Series B close from Illumina spin-out Grail.